Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from BioHarvest Sciences ( (BHST) ).
On August 13, 2025, BioHarvest Sciences Inc. announced the adoption of an amended insider trading policy by its board of directors. The new policy adjusts the trading window to open after the close of trading on the second full trading day following the public release of quarterly or year-end results and to close fifteen days before the due date of these results. This change is expected to provide a more reasonable trading period, potentially impacting the company’s operations by aligning trading activities with financial disclosures.
The most recent analyst rating on (BHST) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on BioHarvest Sciences stock, see the BHST Stock Forecast page.
Spark’s Take on BHST Stock
According to Spark, TipRanks’ AI Analyst, BHST is a Neutral.
BioHarvest Sciences’ strong revenue growth and strategic initiatives are promising, but financial instability and valuation concerns weigh heavily. Technical indicators are positive but suggest caution due to overbought conditions.
To see Spark’s full report on BHST stock, click here.
More about BioHarvest Sciences
BioHarvest Sciences Inc. is a leader in Botanical Synthesis, utilizing its patented technology platform to grow plant-based compounds without cultivating the actual plant. The company operates in two main business areas: as a contract development and production organization (CDMO) for clients seeking novel plant-based compounds, and as a developer of proprietary nutraceutical health and wellness products, including dietary supplements.
Average Trading Volume: 11,334
Technical Sentiment Signal: Buy
Current Market Cap: $157.9M
For a thorough assessment of BHST stock, go to TipRanks’ Stock Analysis page.